Cholesterol, Blood Sugar, and Metabolic Health

How bergamot polyphenols lower LDL cholesterol, improve blood sugar regulation, and support heart health

Bergamot is a citrus fruit native to the Calabria region of southern Italy — best known for giving Earl Grey tea its distinctive floral scent, but increasingly recognized for its remarkable effects on cholesterol and metabolic health. The fruit contains a unique set of polyphenols — including brutieridin, melitidin, neoeriocitrin, naringin, and neohesperidin — that act through multiple pathways to lower LDL cholesterol, reduce triglycerides, and improve blood sugar regulation [1][2]. Multiple clinical trials and meta-analyses have confirmed these effects, making bergamot one of the better-supported natural approaches to lipid management.

How Bergamot Works

Bergamot's active compounds are polyphenols found in the fruit's juice and peel. Unlike most citrus fruits, bergamot produces unusually high concentrations of these compounds — particularly brutieridin and melitidin, which are structurally similar to statin drugs in that they inhibit HMG-CoA reductase, the same enzyme that pharmaceutical statins block to reduce cholesterol production in the liver [2].

Cholesterol-Lowering Mechanisms

Bergamot reduces LDL cholesterol through at least three complementary pathways:

HMG-CoA reductase inhibition: Brutieridin and melitidin directly inhibit this rate-limiting enzyme in cholesterol synthesis, reducing the liver's production of LDL cholesterol. This is the same target as statins, which is why bergamot is sometimes called a "natural statin" — though its inhibition is less potent than pharmaceutical statins [2].

AMPK activation: Bergamot polyphenols activate AMP-activated protein kinase (AMPK), a master metabolic regulator that influences both cholesterol synthesis and glucose uptake. AMPK activation mimics the cellular energy-sensing effects of exercise and caloric restriction, improving insulin sensitivity and reducing liver fat production [2].

Pancreatic cholesterol ester hydrolase inhibition: Bergamot compounds also inhibit this enzyme, which is involved in intestinal cholesterol absorption — a third independent route to lowering circulating LDL [2].

Blood Sugar and Insulin Sensitivity

Beyond lipids, AMPK activation enhances GLUT4 transporter expression on muscle cells, which allows cells to take up glucose from the bloodstream more efficiently. This translates to measurable reductions in fasting blood glucose and HOMA-IR (a measure of insulin resistance) in clinical trials. A 2023 RCT found a 5.1% reduction in fasting plasma glucose and significant improvements in liver enzymes in participants with hypercholesterolemia [5].

Liver Support

The same RCT found significant reductions in liver enzymes — glutamate oxaloacetate transaminase (−7.8%), glutamate pyruvate transaminase (−7.3%), and notably gamma-glutamyl transferase (−34.4%) — suggesting bergamot may help reduce hepatic fat accumulation and mild liver stress associated with dyslipidemia [5].

Practical Dosage and Forms

Standardized extract doses: Most clinical trials use 500–1,000 mg of bergamot fruit extract per day, standardized to polyphenol content. Some trials use lower doses (150 mg of total flavonoids) combined with other ingredients
Duration: Effects become measurable at 4–6 weeks; most trials ran 12 weeks
Forms available: Bergamot polyphenol fraction (BPF), standardized extracts (various brands), and combination products with artichoke, plant sterols, or red yeast rice
Earl Grey tea: While it contains bergamot oil (extracted from the peel), it does not contain therapeutic doses of the polyphenols found in supplement extracts
Safety: Well tolerated in clinical trials; not known to cause the muscle pain (myalgia) associated with pharmaceutical statins. Check with a doctor if you're already on cholesterol-lowering medication

See our berberine page for another well-studied natural compound with complementary effects on blood sugar and cholesterol. For cardiovascular support, see also coenzyme Q10 and omega-3 fatty acids.

Evidence Review

Prospective Study: 6-Month Lipid and Atherosclerosis Outcomes

Toth et al. (PMID 26779019) conducted a 6-month prospective study of bergamot polyphenol fraction (Bergavit®) in subjects with moderate hypercholesterolemia. Participants taking bergamot experienced significant reductions in total cholesterol, triglycerides, and LDL-cholesterol, while HDL-cholesterol increased. Notably, the study measured carotid intima-media thickness (cIMT) — a validated marker of subclinical atherosclerosis — and found it decreased from 1.2 ± 0.4 mm to 0.9 ± 0.1 mm over 6 months. This is a clinically meaningful finding because cIMT progression correlates with future cardiovascular events. The study also showed reduction in small dense LDL particles, which are more atherogenic than larger LDL particles. Study limitation: it was a prospective cohort design rather than a randomized controlled trial.

Systematic Review: Dose-Response and Consistency Across Trials

Lamiquiz-Moneo et al. (PMID 31670973) systematically reviewed 12 studies meeting eligibility criteria out of 442 identified. Across 75% of studies, bergamot produced significant reductions in total cholesterol (−12.3% to −31.3%), LDL-C (−7.6% to −40.8%), and triglycerides (−11.5% to −39.5%). HDL-cholesterol increased in most studies. The review noted heterogeneity in study designs, bergamot formulations, and participant populations — but the directionality of effects was remarkably consistent. The authors identified extract form (polyphenol fraction vs. juice vs. essential oil) as the key determinant of effect size, with standardized polyphenol extracts showing the strongest results.

Meta-Analysis: Pooled Estimates from 14 RCTs

Sadeghi-Dehsahraei et al. (PMID 36251526), published in Phytotherapy Research, pooled 14 randomized controlled trials examining bergamot's effects on lipid profiles. The weighted mean differences showed:

Total cholesterol: −63.60 mg/dL (95% CI: −78.03 to −49.18; p < 0.001)
Triglycerides: −74.72 mg/dL (95% CI: −83.58 to −65.87; p < 0.001)
LDL-C: −55.43 mg/dL (95% CI: −67.26 to −43.60; p < 0.001)
HDL-C: +5.78 mg/dL (95% CI: 3.27 to 8.28; p < 0.001)

These are substantial effect sizes. A 55 mg/dL reduction in LDL, if sustained, corresponds to a meaningful reduction in cardiovascular risk according to established guidelines. The meta-analysis noted that results for nutraceutical combination products containing bergamot were more heterogeneous, and higher-quality confirmatory trials are still needed.

3-Arm RCT: Lipids, Glucose, and Liver Enzymes

Fogacci et al. (PMID 37732027) conducted a rigorous 3-arm, double-blind, placebo-controlled trial in 75 subjects with hypercholesterolemia. Participants received either placebo, a bergamot-based nutraceutical alone, or a combination formula with bergamot phytocomplex (200 mg Brumex®), plant sterols, opuntia extract, and thiamine. After 12 weeks, the active arm showed:

Total cholesterol: −14.6%
LDL-C: −19.9%
Triglycerides: −13.1%
HDL-C: +6.9%
Fasting plasma glucose: −5.1%
Gamma-glutamyl transferase: −34.4%

The liver enzyme reductions are noteworthy — GGT is a sensitive marker of liver stress and fatty liver disease, and a 34% reduction suggests bergamot may have hepatoprotective effects beyond its lipid-lowering activity. The study's limitation is that bergamot was used in combination with other ingredients, making it difficult to isolate the bergamot-specific contribution. However, the bergamot-alone arm (using only Brumex®) also showed significant lipid improvements.

Overall Evidence Assessment

The evidence base for bergamot and lipid management is among the stronger cases in the nutraceutical space. Multiple independent RCTs and meta-analyses consistently show LDL reductions of 15–30%, triglyceride reductions, and HDL increases. The mechanisms are biologically plausible and partially elucidated. Blood sugar effects are promising but based on fewer studies. The primary limitations are the use of proprietary standardized extracts in most studies (making it unclear how results translate to different products), relatively short trial durations, and predominantly Italian research groups. Still, for someone seeking a non-statin option for mildly elevated cholesterol, bergamot has a genuinely compelling evidence base.

References

Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective StudyToth PP, Patti AM, Nikolic D, Giglio RV, Castellino G, Biancucci T, Geraci F, David S, Montalto G, Rizvi AA, Rizzo M. Frontiers in Pharmacology, 2016. PubMed 26779019 →
Clinical application of bergamot (Citrus bergamia) for reducing high cholesterol and cardiovascular disease markersNauman MC, Johnson JJ. Integrative Food and Nutrition Metabolism, 2019. PubMed 31057945 →
Effect of bergamot on lipid profile in humans: A systematic reviewLamiquiz-Moneo I, Giné-González J, Mateo-Gallego R, Marco-Benedí V, Pérez-Calahorra S, Bea AM, Ferrando J, Civeira F, Cenarro A. Critical Reviews in Food Science and Nutrition, 2020. PubMed 31670973 →
The effect of bergamot supplementation on lipid profiles: A systematic review and meta-analysis of randomized controlled trialsSadeghi-Dehsahraei H, Esmaeili Gouvarchin Ghaleh H, Mirnejad R, Parastouei K. Phytotherapy Research, 2022. PubMed 36251526 →
Comparative effect of a nutraceutical compound based on a flavonoid complex from bergamot on plasma lipids, glucose metabolism, and liver enzymes: a 3-arm, double-blind, placebo-controlled, randomized clinical trialFogacci F, Di Micoli V, Veronesi M, Cicero AFG. Archives of Medical Science, 2023. PubMed 37732027 →